162. Pemphigoid
70 clinical trials,   117 drugs   (DrugBank: 46 drugs),   30 drug target genes,   128 drug target pathways
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04499235 (ClinicalTrials.gov) | January 30, 2020 | 31/7/2020 | A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid | Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid | Pemphigoid, Bullous | Drug: Mometasone furoate;Drug: AKST4290;Drug: Placebo | Alkahest, Inc. | NULL | Recruiting | 60 Years | 95 Years | All | 30 | Phase 2 | Germany |